Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas

Oncogene

Volumn 36, Issue 21, 2017, Pages 2921-2929

  Tonelli, C ^a   Morelli, M J ^b   Sabo A ^b   Verrecchia, A ^a   Rotta, L ^a   Capra, T ^a   Bianchi, S ^b   Campaner, S ^b   Amati, B ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GENOMIC DNA; MYC PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CHROMATIN; CONTROLLED STUDY; ENHANCER REGION; GENE CONTROL; GENE INDUCTION; GENE REPRESSION; GENETIC ANALYSIS; GENOME; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; NIH 3T3 CELL LINE; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENOME-WIDE ASSOCIATION STUDY; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NIH 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85009754856     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.443     Document Type: Article

References (48)

1. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
2. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-370.
3. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-1334.
4. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665.
5. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
6. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011; 121: 893-904.
7. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6: 1029-1035.
8. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001; 27: 206-216.
9. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005; 37: 718-726.
10. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514.
11. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
12. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
13. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-318.
14. Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science 2004; 303: 844-848.
15. Campaner S, Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div 2012; 7: 6.
16. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS et al. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction. Cancer Cell 2010; 18: 231-243.
17. Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R et al. Diverse stresses dramatically alter genome-wide p53 binding and transac-tivation landscape in human cancer cells. Nucleic Acids Res 2013; 41: 7286-7301.
18. Tonelli C, Morelli MJ, Bianchi S, Rotta L, Capra T, Sabò A et al. Genome-wide analysis of p53 transcriptional programs in B cells upon exposure to genotoxic stress in vivo. Oncotarget 2015; 6: 24611-24626.
19. Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res 2014; 42: D142-D147.
20. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
21. Chang GS, Chen XA, Park B, Rhee HS, Li P, Han KH et al. A comprehensive and high-resolution genome-wide response of p53 to stress. Cell Rep 2014; 8: 514-527.
22. Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagen-esis. Nature 2014; 511: 488-492.
23. Sammons MA, Zhu J, Drake AM, Berger SL. TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. Genome Res 2015; 25: 179-188.
24. Su D, Wang X, Campbell MR, Song L, Safi A, Crawford GE et al. Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation. PLoS Genet 2015; 11: e1004885.
25. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell 2012; 46: 30-42.
26. Kenzelmann Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 2013; 27: 1016-1031.
27. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG et al. Role of p53 serine 46 in p53 target gene regulation. PloS One 2011; 6: e17574.
28. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19: 1992-2002.
29. Schlereth K, Heyl C, Krampitz AM, Mernberger M, Finkernagel F, Scharfe M et al. Characterization of the p53 cistrome-DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genet 2013; 9: e1003726.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
31. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
32. Renault VM, Thekkat PU, Hoang KL, White JL, Brady CA, Kenzelmann Broz D et al. The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene 2011; 30: 3207-3221.
33. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-219.
34. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85-94.
35. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
36. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659.
37. He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS. Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res 2012; 22: 1015-1025.
38. Sabo PJ, Kuehn MS, Thurman R, Johnson BE, Johnson EM, Cao H et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 2006; 3: 511-518.
39. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
40. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
41. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
42. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-930.
43. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-628.
44. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
45. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.
46. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics 2011; 27: 1017-1018.
47. Huang, da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
48. Huang, da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.